Unpublished And Under Review? US FDA’s CBD Policy Draft Guidance Still Has Industry Talking
Supplements containing hemp-derived cannabidiols aren’t typical products subject to FDA’s regulatory oversight, and the document stating its thinking on enforcement in the market submitted to the Office of Management and Budget isn’t a typical draft guidance.
You may also be interested in...
FDA schedules public meeting for 19 November to discuss sex and gender differences in the use and response to cannabidiols. The meeting will address the issue of CBD use in pregnancy, for which no human data currently is available.
Responsible CBD supplement marketers are disadvantaged against bad actors with products taking up shelf space in “disloyal” retailers as federal regulatory limbo drags on, says nutritional science expert Duffy McKay. Patchwork of state regulations on CBD also create challenges.
House Energy and Commerce members are expected soon to introduce a bill to make lawful the use of CBD and other hemp-derived ingredients, other than THC, in dietary supplements. Capitol Hill interest in proposing legislation, says Sen. Wyden , will grow if FDA doesn’t bring some order to the CBD space.